Undisclosed

all catalysts(0)

nothing on the calendar yet

News(10)

• Foghorn cuts 40% of workforce
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
  Foghorn Therapeutics is laying off 40% of its workforce after a long-running collaboration with Eli Lilly collapsed over disappointing phase 1 data.
  fiercebiotech · 3d ago
• Beam sues 2 biotechs, alleging theft of base editing trade secrets
  Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.
  biopharma_dive · 4d ago
• Precision Neuroscience taps $250M in Series D funding for brain-computer interface
  Precision Neurosciences, which specializes in brain-computer interface technology, raised $250 million in an oversubscribed Series D financing round.
  fiercebiotech · 6d ago
• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 6d ago
• Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
  The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.
  biospace · 9d ago
• Growth mode: 3 biotechs that are staffing up after series B raises
  Biotechs that announced series B financing this year and are expanding their workforces include one that raised $2.1 billion and has partnerships with Eli Lilly, Johnson & Johnson and Novartis.
  biospace · 10d ago
• Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
  Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in milestones.
  fiercebiotech · 10d ago
• Novartis bets up to $900M for radioligand therapy from China’s BoomRay
  Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.
  biospace · 10d ago
• GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
  After inking a T cell engager pact with Chimagen Biosciences a few years ago, GSK is back for more, this time acquiring a multiple myeloma program from the antibody specialist.
  biospace · 18d ago